Frequency of Fanconi anemia in Brazil and efficacy of screening for the FANCA 3788-3790del mutation

Brazilian Journal of Medical and Biological Research

N. Magdalena²  D.v. Pilonetto¹  M.a. Bitencourt¹  N.f. Pereira¹  R.c. Ribeiro¹  M. Jeng¹  R. Pasquini¹ 

[1] ,Universidade Federal do Paraná Hospital de Clínicas Departamento de Pediatria

关键词: Fanconi anemia;    FANCA;    3788-3790del mutation;    Genetic screening;   

DOI  :  10.1590/S0100-879X2005000500003

来源: SciELO

【 摘 要 】

Fanconi anemia (FA) is an autosomal recessive genetic disease characterized by progressive bone marrow failure, susceptibility to cancer and multiple congenital anomalies. There is important clinical variability among patients and the knowledge of factors which might predict outcome would greatly help the decision making regarding the choices of treatment and the appropriate time to start it. Future studies of the possible correlation between specific mutations with specific clinical presentations will provide the answer to one of these factors. At our Center we standardized a rapid and precise screening test using a mismatch PCR assay for a specific mutation (3788-3790del in exon 38 of gene FANCA) in Brazilian FA patients. We present the results obtained after screening 80 non-consanguineous FA patients referred from all regions of Brazil with a clinical diagnosis of FA supported by cellular hypersensitivity to diepoxybutane. We were able to detect the 3788-3790del allele in 24 of the 80 (30%) FA patients studied. Thirteen of the 80 (16.25%) were homozygotes and 11 of the 80 (13.75%) were compound heterozygotes, thus confirming the high frequency of the FANCA 3788-3790del mutation in Brazilian FA patients. The identification of patients with specific mutations in the FA genes may lead to a better clinical description of this condition, also providing data for genotype-phenotype correlations, to a better understanding of the interaction of this specific mutation with other mutations in compound heterozygote patients, and ultimately to the right choices of treatment for each patient with improvement of the prognosis on future studies.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License